About this Medicine article

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab by Kotaka, Masahito; Xu, Ruihua; Muro, Kei; Park, Young Suk; Morita, Satoshi; Iwasa, Satoru; Uetake, Hiroyuki; Nishina, Tomohiro; Nozawa, Hiroaki; Matsumoto, Hiroshi; Yamazaki, Kentaro; Han, Sae-Won; Wang, Wei; Ahn, Joong Bae; Deng, Yanhong; Cho, Sang-Hee; Ba, Yi; Lee, Keun-Wook; Zhang, Tao; Satoh, Taroh; Buyse, Marc E.; Ryoo, Baek-Yeol; Shen, Lin; Sakamoto, Junichi; Kim, Tae Won is a Medicine article available to read on EtoBox.

Author

Kotaka, Masahito; Xu, Ruihua; Muro, Kei; Park, Young Suk; Morita, Satoshi; Iwasa, Satoru; Uetake, Hiroyuki; Nishina, Tomohiro; Nozawa, Hiroaki; Matsumoto, Hiroshi; Yamazaki, Kentaro; Han, Sae-Won; Wang, Wei; Ahn, Joong Bae; Deng, Yanhong; Cho, Sang-Hee; Ba, Yi; Lee, Keun-Wook; Zhang, Tao; Satoh, Taroh; Buyse, Marc E.; Ryoo, Baek-Yeol; Shen, Lin; Sakamoto, Junichi; Kim, Tae Won

Publisher

Chinese Electronic Periodical Services; Springer (Biomed Central Ltd.); BioMed Central; Austin TX; Guangzhou: Landes Bioscience; Zhongshan yi ke da xue fu shu zhong liu yi yuan; London England: BioMed Central; Springer Science and Business Media LLC; Editorial Office of Chinese Journal of Cancer (ISSN 1000-467X)

Published

2016

Field

Medicine (Health Sciences)